Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3

Molecular Therapy

Volumn 16, Issue 11, 2008, Pages 1789-1797

  Marozin, Sabrina ^a   Altomonte, Jennifer ^a   Stadler, Florian ^b   Thasler, Wolfgang E ^b   Schmid, Roland M ^a   Ebert, Oliver ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DOUBLE STRANDED RNA; INTERFERON; INTERFERON REGULATORY FACTOR 3; ISOPROTEIN; NEUTRALIZING ANTIBODY;

ALTERNATIVE RNA SPLICING; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PROTEIN DEFECT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLICEOSOME; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS INFECTION; VIRUS REPLICATION;

ALTERNATIVE SPLICING; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HEPATOCYTES; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; LIVER NEOPLASMS; ONCOLYTIC VIRUSES; PROTEIN ISOFORMS; RNA, DOUBLE-STRANDED; VESICULOVIRUS; VIRUS REPLICATION;

VESICULAR STOMATITIS VIRUS;

EID: 54949096928     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.201     Document Type: Article

References (49)

1. Giannelli, G and Antonaci, S (2006). Novel concepts in hepatocellular carcinoma: From molecular research to clinical practice. J Clin Gastroentero1 40: 842-846.
2. Vollmer, CM, Ribas, A, Butterfield, LH, Dissette, VB, Andrews, KI, Eilber, FC et al. (1999). p53 selective and nonselective replication Of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 59: 4369-4374.
3. Hallenbeck, PL, Chang, YN, Hay, C, Golightly, D, Stewart, D, Lin, J et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 10: 1721-1733.
4. Huang, TG, Savontaus, MJ, Shinozaki, K, Sauter, BV and Woo, SL (2003). Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 10: 1241-1247.
5. Miyatake, SI, Tani, S, Feigenbaum, F, Sundaresan, P, Toda, H, Narumi, O et al. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 6: 564-572.
6. Pawlik, TM, Nakamura, H, Yoon, SS, Mullen, JT, Chandrasekhar, S, Chiocca, EA et al. (2000). Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpes virus. Cancer Res 60: 2790-2795.
7. Ebert, O, Shinozaki, K, Huang, TG, Savontaus, MJ, Garcia-Sastre, A and Woo, SL (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 63: 3605-3611.
8. Kemeny, N, Brown, K, Covey, A, Kim, T, Bhargava, A, Brody, L et al. (2006). Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214-1224.
9. Rose, JK and Whitt, MA (2001). Rhabdoviridae: The viruses and their replication. In: Knipe, DM and Howley, PM (eds). Fields Virology, 4th edn. Lippincott Williams & Wilkins: Philadelphia. pp. 1221-1242.
10. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6 821-825.
11. Balachandran, S and Barber, GN (2000). Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50: 135-138.
12. Ebert, O, Shinozaki, K, Kournioti, C, Park, MS, Garcia-Sastre, A and Woo, SL (2004). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64: 3265-3270.
13. Shinozaki, K, Ebert, O, Kournioti, C, Tai, YS and Woo, SL (2004). Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9: 368-376.
14. Shinozaki, K, Ebert, O and Woo, SL (2005). Eradication of advanced hepatacellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41: 196-203.
15. Petersen, JM, Her, LS, Varvel, V, Lund, E and Dahlberg, JE (2000). The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 20: 8590-8601.
16. von Kobbe, C, van Deursen, JM, Rodrigues, JP, Sitterlin, D, Bachi, A, Wu, X et al. (2000). Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 6: 1243-1252.
17. Ahmed, M, McKenzie, MO, Puckett, S, Hojnacki, M, Poliquin, L and Lyles, DS (2003). Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77: 4646-4657.
18. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
19. Desforges, M, Charron, J, Berard, S, Beausoleil, S, Stojdl, DF, Despars, G et al. (2001). Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res 76: 87-102.
20. Stetson, DB and Medzhitov, R (2006). Type I interferons in host defense. Immunity 25: 373-381.
21. Dunn, GP, Koebel, CM and Schreiber, RD (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
22. Parmar, S and Platanias, LC (2003). Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 15: 431-439.
23. Yoneyama, M, Kikuchi, M, Natsukawa, T, Shinobu, N, Imaizumi, T, Miyagishi, M et al. (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-737.
24. Fitzgerald, KA, McWhirter, SM, Faia, KL, Rowe, DC, Latz, E, Golenbock, DT et al. (2003). IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4: 491-496.
25. Sharma, S, tenOever, BR, Grandvaux, N, Zhou, GP, Lin, R and Hiscom J (2003). Triggering the interferon antiviral response through an IKK-related pathway. Science 300; 1148-1151.
26. Servant, MJ, Grandvaux, N, tenOever, BR, Duguay, D, Lin, R and Hiscott, J (2003). Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J. Biol Chem 278: 9441-9447.
27. Karpova, AY, Howley, PM and Ronco, LV (2000). Dual utilization of an acceptor/donor splice site governs the alternative splicing of the IRF-3 gene. Genes Dev 14: 2813-2818.
28. Karpova, AY, Ronco, LV and Howley, PM (2001). Functional characterization of interferon regulatory factor 3a (IRF-3a), an alternative splice isoform of IRF-3. Mol Cell Biol 21: 4169-4176.
29. Jiang, Z, Mak, TW, Sen, G and Li, X (2004). Toll-like receptor 3-mediated activation of NF-κB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-β. Proc Natl Acad Sci USA 101: 3533-3538.
30. Le Goffic, R, Pothlichet, J, Vitour, D, Fujita, T, Meurs, E, Chignard, M et al. (2007). Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 178: 3368-3372.
31. Loo, YM and Gale, M Jr. (2007). Viral regulation and evasion of the host response. Curr Top Microbiol Immunol 316: 295-313.
32. Li, K, Chen, Z, Kato, N, Gale, M Jr. and Lemon, SM (2005). Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-β production in hepatocytes. J Biol Chem 280: 16739-16747.
33. Alexopoulou, L, Holt, AC, Medzhitov, R and Flavell, RA (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738.
34. Maher, SG, Romero-Weaver, AL, Scarzello, AJ and Gamero, AM (2007). Interferon: Cellular executioner or white knight? Curr Med Chem 14: 1279-1289.
35. Keskinen, P, Nyqvist, M, Sareneva, T, Pirhonen, J, Melen, K and Julkunen, I (1999). Impaired antiviral response in human hepatoma cells. Virology 263: 364-375.
36. Hiscott, J, Pitha, P, Genin, P, Nguyen, H, Heylbroeck, C, Mamane, Y et al. (1999). Triggering the interferon response: The role of IRF-3 transcription factor. J Interferon Cytokine Res 19: 1-13.
37. Li, XD, Sun, L, Seth, RB, Pineda, G and Chen, ZJ (2005). Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 102: 17717-17722.
38. Trottier, MD, Lyles, DS and Reiss, CS (2007). Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol 13: 433-445.
39. Noser, JA, Mael, AA, Sakuma, R, Ohmine, S, Marcato, P, Wk Lee, P et al. (2007). The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells. Mol Ther 15: 1531-1536.
40. Qin, BY, Liu, C, Lam, SS, Srinath, H, Delston, R, Correia, JJ et al. (2003). Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol 10: 913-921.
41. Takahasi, K, Suzuki, NN, Horiuchi, M, Mori, M, Suhara, W, Okabe, Y et al. (2003). X-ray crystal structure of IRF-3 and its functional implications. Nat Struct Biol 10: 922-927.
42. Koenig Merediz, SA, Schmidt, M, Hoppe, GJ, Alfken, J, Meraro, D, Levi, BZ et al. (2000). Cloning of an interferon regulatory factor 2 isoform with different regulatory ability. Nucleic Acids Res 28 4219-4224.
43. Lee, EJ, Jo, M, Park, J, Zhang, W and Lee, JH (2006). Alternative splicing variants of IRF-1 lacking exons 7, 8, and 9 in cervical cancer. Biochem Biophys Res Commun 347: 882-888.
44. Shamay, M, Agami, R and Shaul, Y (2001). HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer. Oncogene 20: 6811-6819.
45. Binder, M, Kochs, G, Bartenschlager, R and Lohmann, V (2007). Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46: 1365-1374.
46. Lanfor, RE, Guerra, B, Lee, H, Averett, DR, Pfeiffer, B, Chavez, D et al. (2003). Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, Poly(I)-Poly(C), tumor necrosis factor alpha, and Ribavirin in hepatitis C virus subgenomic replicons. J Virol 77: 1092-1104.
47. Dansako, H, Ikeda, M and Kato, N (2007). Limited suppression of the interferon-β production by hepatitis C virus serine protease in cultured human hepatocytes. FEBS J 274: 4161-4176.
48. Thasler, WE, Weiss, TS, Schillhorn, K, Stoll, PT, Irrgang, B and Jauch, KW (2003). Charitable state-controlled foundation human tissue and cell research: Ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4: 49-56.
49. Ebert, O, Harbaran, S, Shinozaki, K and Woo, SL (2005). Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 12: 350-358.